Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer - Episode 3

Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials

,

This discussion explores the occurrence and risk factors of neutropenia associated with SG treatment, comparing clinical practice experiences with trial data.

EP. 1: Overview of Current ADCs in Breast Cancer
EP. 2: ADCs in Breast Cancer: Mechanism of Action, and Components
Now Viewing
EP. 3: Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials
EP. 4: Expert Perspectives on the Management of SG-Related Neutropenia
EP. 5: Navigating SG-related Diarrhea
EP. 6: Expert Insights: SG Adverse Events Management including Alopecia & Nausea
EP. 7: Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies
EP. 8: Clinical Management Considerations: Pneumonitis associated with T-DXd
EP. 9: Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies
EP. 10: Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer
EP. 11: Future Perspectives on ADCs in Breast Cancer
EP. 12: Expert Insights: Investigational ADCs Safety Profiles
EP. 13: Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs

Video content above is prompted by the following:

  • Let’s dive deeper into some of the specific adverse events that we may see with SG in our clinical practice….
  • How often do you see neutropenia in your clinical practice? How does it compare to the rates reported in clinical trials (ASCENT, TROPiCS-02)?
  • Are there risk factors that can help predict those who are at higher risk for developing neutropenia?